Literature DB >> 23749180

Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain.

S Haupt, C Gamell, K Wolyniec, Y Haupt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23749180      PMCID： PMC3679466          DOI： 10.1038/cdd.2013.51

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  19 in total

1.  Angiogenesis: escape from hypoxia.

Authors:  Mathew L Coleman; Peter J Ratcliffe
Journal:  Nat Med       Date:  2009-05       Impact factor: 53.440

Review 2.  Hallmarks of cancer: interactions with the tumor stroma.

Authors:  Kristian Pietras; Arne Ostman
Journal:  Exp Cell Res       Date:  2010-03-06       Impact factor: 3.905

Review 3.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

4.  Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation.

Authors:  Smitha Pillai; Michelle Kovacs; Srikumar Chellappan
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

5.  p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner.

Authors:  Yoseph Addadi; Neta Moskovits; Dorit Granot; Guillermina Lozano; Yaron Carmi; Ron N Apte; Michal Neeman; Moshe Oren
Journal:  Cancer Res       Date:  2010-10-15       Impact factor: 12.701

Review 6.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis.

Authors:  Shuji Ogino; Katsuhiko Nosho; Kaori Shima; Yoshifumi Baba; Natsumi Irahara; Gregory J Kirkner; Aditi Hazra; Immaculata De Vivo; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

8.  Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.

Authors:  Isabel M Pires; Zuzana Bencokova; Manuela Milani; Lisa K Folkes; Ji-Liang Li; Mike R Stratford; Adrian L Harris; Ester M Hammond
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

Review 9.  Reciprocal influence of the p53 and the hypoxic pathways.

Authors:  A Sermeus; C Michiels
Journal:  Cell Death Dis       Date:  2011-05-26       Impact factor: 8.469

Review 10.  Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression.

Authors:  Masayuki Shimoda; Kieran T Mellody; Akira Orimo
Journal:  Semin Cell Dev Biol       Date:  2009-10-24       Impact factor: 7.727
View more
  5 in total

1.  TAp73 promotes anti-senescence-anabolism not proliferation.

Authors:  Massimiliano Agostini; Maria Victoria Niklison-Chirou; Maria Valeria Catani; Richard A Knight; Gerry Melino; Alessandro Rufini
Journal:  Aging (Albany NY)       Date:  2014-11       Impact factor: 5.682

2.  TAp73 promotes anabolism.

Authors:  Ivano Amelio; Alexey A Antonov; Maria Valeria Catani; Renato Massoud; Francesca Bernassola; Richard A Knight; Gerry Melino; Alessandro Rufini
Journal:  Oncotarget       Date:  2014-12-30

3.  Bioinformatics analysis of the serine and glycine pathway in cancer cells.

Authors:  Alexey Antonov; Massimiliano Agostini; Maria Morello; Marilena Minieri; Gerry Melino; Ivano Amelio
Journal:  Oncotarget       Date:  2014-11-30

4.  p53 siRNA - a therapeutic tool with significant implication in the modulation of apoptosis and angiogenic pathways.

Authors:  Ovidiu Braicu; Valentina Pileczki; Cornelia Braicu; Patriciu Achimas-Cadariu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Clujul Med       Date:  2015-07-01

5.  Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.

Authors:  J-L Wang; Z-F Chen; H-M Chen; M-Y Wang; X Kong; Y-C Wang; T-T Sun; J Hong; W Zou; J Xu; J-Y Fang
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.